The science behind rapid diagnostics development for CA-LRTI

T. Bachmann (Edinburgh, United Kingdom)

Source: Value-Dx event 2019: VALUE-Dx kick off meeting and course
Number: 2
Disease area: -

PDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Bachmann (Edinburgh, United Kingdom). The science behind rapid diagnostics development for CA-LRTI. Value-Dx event 2019: VALUE-Dx kick off meeting and course

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Opportunities of bacteriological diagnostics of a tuberculosis of a lung in a modern stage
Source: Annual Congress 2008 - Diagnosis of tuberculosis: problems and perspectives
Year: 2008

Facts and perspectives in the development of new diagnostics
Source: Annual Congress 2008 - New insights into tuberculosis control
Year: 2008

Diagnosing asthma in the era of personalised medicine: biology, physiology and imaging
Source: Virtual Congress 2021 – Precision medicine in asthma and COPD
Year: 2021

Innovative tools for diagnosis and prevention of paediatric tuberculosis
Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis
Year: 2019

Sputum induction for assessment of biomarkers in early development of new drugs for respiratory disease in a proof of concept setting
Source: International Congress 2016 – Airway biomarkers
Year: 2016

Basic science and diagnosis
Source: School Course 2013 - Cystic Fibrosis
Year: 2013

The new horizons of molecular diagnosis: do we still need conventional microbiology?
Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination
Year: 2012

Contemporary diagnostics and staging
Source: Annual Congress 2012 - PG10 An update on mesothelioma diagnostics and treatment
Year: 2012

Tuberculosis prevention must integrate technological and basic care innovation
Source: Eur Respir J 2016; 48: 1531-1532
Year: 2016

From traditional bacteriology to rapid molecular methods: the revolution is going on
Source: Annual Congress 2012 - PG7 TB and MDR-/XDR-TB: what is new in diagnosis, treatment and follow-up (TB PAN-NET)
Year: 2012

Biomarkers and rapid diagnostics in antibiotic stewardship
Source: International Congress 2015 – PG14 Antibiotic stewardship for respiratory infections
Year: 2015

Latest insights and challenges in tuberculosis vaccine development
Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management
Year: 2019

COVID-19 vaccines: immunology, regulation and clinical management
Source: Eur Respir Monogr 2021; 94: 244-260
Year: 2021

Characterisation of clinical phenotypes is mandatory for the development of new drugs
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014

Perspectives of therapeutic innovation from current progress in the pathobiology of pulmonary hypertension
Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease
Year: 2020